Please login to the form below

Not currently logged in

Apeiron bolsters management board

Peter Llewellyn-Davies joins as its CFO and CBO

Van De WinkelViennese cancer-immunotherapy focused group Apeiron Biologics has appointed a new chief financial officer and chief business officer in the form of Peter Llewellyn-Davies.

With more than 25 years’ experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech and pharma industries, Llewellyn-Davies most recently ran his own consulting firm Accellerate Partners.

He said: “Apeiron is currently amongst the most compelling privately owned European biotech companies and I am looking forward to working together with the team to jointly lead Apeiron through the next phase of growth.”

During the course of his career, Llewellyn-Davies supported Medigene’s strategy to form an immunotherapy company and he assisted in initial public offerings for Wilex.

Dr Hans Loibner, chief executive officer, Apeiron, said: “Peter’s expertise, which has been proven by many international capital market transactions, is highly welcome, and he is an ideal addition to support our growth strategy.

“I very much look forward to working hand in hand with him.”

7th November 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....